Delivering the Future – Where AI Meets Nanomedicine; Initiate at Buy

Research evidence excerpt

Delivering the Future – Where AI Meets Nanomedicine; Initiate at Buy

China (PRC) | Life Science Tools & Diagnostics

Metis TechBio EquityJulyResearch8, 2026

INITIATING COVERAGEDelivering the Future — Where AI Meets

RATING BUYNanomedicine; Initiate at Buy

PRICE HK$13.80^

METiS is building a differentiated AI-biotech engine spanning small

molecules, RNA/LNPs and proteins. Its NanoForge platform combines AI PRICE TARGET | % TO PT HK$30.00 | +117%

with wet-lab validation, with the world's largest ionizable lipid library enables 52W HIGH-LOW HK$29.98 - HK$11.53

FIC delivery to muscle, heart and brain, alongside BIC performance in lung FLOAT (%) | ADV MM (USD) 42.4% | 38.54

and liver delivery. Following the landmark Deerfield deal and 30+ ongoing MARKET CAP HK$16.3B | HK$16.3B

BD discussions, we exp. further partnerships with global pharma. Initiate at TICKER 7666 HK ^Prior trading day's closing price unless otherwise

Buy with HK$30 PT. noted.

AI + Nanomaterials: From Molecular Design to Initial Clinical Validation - METiS has built FY (Dec) CHANGE TO JEFe JEF vs CONS

a differentiated AI-drug development engine spanning small molecules, RNAs+LNPs, and 2026 2027 2026 2027

proteins, powered by its prop NanoForge dry-/wet-lab ecosystem. Unlike pure software REV NA NA NA NA

platforms, METiS integrates experimental biology into AI models, creating a self-reinforcing EPS NA NA NA NA

advantage in drug design and development. Refer to our deep dives: AI 1.0 - Artificial Intelligence,

Real Care, AI 2.0 - Healthcare's Next Prescription.

2026 (RMB) 1Half 2Half FY

Its lead asset, MTS-004, serves as the first real-world proof of concept. Developed using EPS -- -- (0.30)

the AiTEM platform, MTS-004 compressed formulation timelines from 1-2 yrs to <3 mo PREV